Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 183

1.

Role of IL-28B genetic variants in HCV-related liver disease severity in patients with different viral genotypes.

Huang CI, Huang CF, Yeh ML, Lin YH, Liang PC, Liu SV, Hsieh MH, Lin ZY, Chen SC, Huang JF, Chuang WL, Dai CY, Yu ML.

Medicine (Baltimore). 2018 Mar;97(10):e9782. doi: 10.1097/MD.0000000000009782.

2.

Association of gadolinium-enhanced magnetic resonance imaging with hepatic fibrosis and inflammation in primary sclerosing cholangitis.

Keller S, Aigner A, Zenouzi R, Kim AC, Meijer A, Weidemann SA, Krech T, Lohse AW, Adam G, Schramm C, Yamamura J.

PLoS One. 2018 Mar 7;13(3):e0193929. doi: 10.1371/journal.pone.0193929. eCollection 2018.

3.

CD133 expression in cancer cells predicts poor prognosis of non-mucin producing intrahepatic cholangiocarcinoma.

Cai X, Li J, Yuan X, Xiao J, Dooley S, Wan X, Weng H, Lu L.

J Transl Med. 2018 Mar 6;16(1):50. doi: 10.1186/s12967-018-1423-9.

4.

The Flavonoid Quercetin Ameliorates Liver Inflammation and Fibrosis by Regulating Hepatic Macrophages Activation and Polarization in Mice.

Li X, Jin Q, Yao Q, Xu B, Li L, Zhang S, Tu C.

Front Pharmacol. 2018 Feb 9;9:72. doi: 10.3389/fphar.2018.00072. eCollection 2018.

5.

Mice lacking ARV1 have reduced signs of metabolic syndrome and non-alcoholic fatty liver disease.

Gallo-Ebert C, Francisco J, Liu HY, Draper R, Modi K, Hayward MD, Jones BK, Buiakova O, McDonough V, Nickels JT Jr..

J Biol Chem. 2018 Apr 20;293(16):5956-5974. doi: 10.1074/jbc.RA117.000800. Epub 2018 Feb 28.

PMID:
29491146
6.

Quantitative assessment of liver fibrosis (qFibrosis) reveals precise outcomes in Ishak "stable" patients on anti-HBV therapy.

Sun Y, Zhou J, Wu X, Chen Y, Piao H, Lu L, Ding H, Nan Y, Jiang W, Wang T, Liu H, Ou X, Wee A, Theise ND, Jia J, You H.

Sci Rep. 2018 Feb 14;8(1):2989. doi: 10.1038/s41598-018-21179-2.

7.

Protective effects of Mentha piperita L. leaf essential oil against CCl4 induced hepatic oxidative damage and renal failure in rats.

Bellassoued K, Ben Hsouna A, Athmouni K, van Pelt J, Makni Ayadi F, Rebai T, Elfeki A.

Lipids Health Dis. 2018 Jan 9;17(1):9. doi: 10.1186/s12944-017-0645-9.

8.

Histopathological evaluation of liver fibrosis and cirrhosis regression.

Lo RC, Kim H.

Clin Mol Hepatol. 2017 Dec;23(4):302-307. doi: 10.3350/cmh.2017.0078. Epub 2017 Dec 20. Review.

9.

Comparison of clinicopathological characteristics between cirrhotic and non-cirrhotic patients with intrahepatic cholangiocarcinoma: A large-scale retrospective study.

Yuan L, Luo X, Lu X, Yi B, Chu K, Cai Q, Jiang X.

Mol Clin Oncol. 2017 Oct;7(4):615-622. doi: 10.3892/mco.2017.1387. Epub 2017 Aug 22.

10.

Cytotoxicity, hemolysis and in vivo acute toxicity of 2-hydroxy-3-anilino-1,4-naphthoquinone derivatives.

de Sena Pereira VS, Silva de Oliveira CB, Fumagalli F, da Silva Emery F, da Silva NB, de Andrade-Neto VF.

Toxicol Rep. 2016 Sep 16;3:756-762. doi: 10.1016/j.toxrep.2016.09.007. eCollection 2016.

11.

Impact of rs12979860 polymorphism on liver morphology in chronic HCV infection.

Łapiński TW, Rogalska-Płonska M, Panasiuk A, Kowalczuk O, Nikliński J, Flisiak R.

Clin Exp Hepatol. 2015 May;1(1):12-16. doi: 10.5114/ceh.2015.51374. Epub 2015 Apr 30.

12.

The effect of the TM6SF2 E167K variant on liver steatosis and fibrosis in patients with chronic hepatitis C: a meta-analysis.

Liu Z, Que S, Zhou L, Zheng S, Romeo S, Mardinoglu A, Valenti L.

Sci Rep. 2017 Aug 24;7(1):9273. doi: 10.1038/s41598-017-09548-9.

13.

CHRONIC HEPATITIS IN PATIENTS OF CHRONIC RENAL FAILURE.

Narula AS, Chaudhury NR, Thakur SK, Karloopia SD, Kolhe VS, Chauhan SS.

Med J Armed Forces India. 1998 Apr;54(2):148-150. doi: 10.1016/S0377-1237(17)30508-7. Epub 2017 Jun 26. No abstract available.

14.

Use of aspartate aminotransferase to platelet ratio to reduce the need for FibroScan in the evaluation of liver fibrosis.

Wong S, Huynh D, Zhang F, Nguyen NQ.

World J Hepatol. 2017 Jun 18;9(17):791-796. doi: 10.4254/wjh.v9.i17.791.

15.

IP-10 Expression in Patients with Chronic HBV Infection and Its Ability to Predict the Decrease in HBsAg Levels after Treatment with Entecavir.

Zhao K, Yang T, Sun M, Zhang W, An Y, Chen G, Jin L, Shang Q, Song W.

Mol Cells. 2017 Jun 30;40(6):418-425. doi: 10.14348/molcells.2017.0051. Epub 2017 Jun 14.

16.

Identification of groups with poor cost-effectiveness of peginterferon plus ribavirin for naïve hepatitis C patients with a real-world cohort and database.

Tsai PC, Liu TW, Tsai YS, Ko YM, Chen KY, Lin CC, Huang CI, Liang PC, Lin YH, Hsieh MY, Hou NJ, Huang CF, Yeh ML, Lin ZY, Chen SC, Dai CY, Chuang WL, Huang JF, Yu ML.

Medicine (Baltimore). 2017 Jun;96(22):e6984. doi: 10.1097/MD.0000000000006984.

17.

Diversity of the association of serum levels and genetic variants of MHC class I polypeptide-related chain A with liver fibrosis in chronic hepatitis C.

Huang CF, Huang CI, Yeh ML, Wang SC, Chen KY, Ko YM, Lin CC, Tsai YS, Tsai PC, Lin ZY, Chen SC, Dai CY, Huang JF, Chuang WL, Yu ML.

Oncotarget. 2017 May 16;8(20):32618-32625. doi: 10.18632/oncotarget.15941.

18.

Noninvasive scoring system for significant inflammation related to chronic hepatitis B.

Hong MZ, Ye L, Jin LX, Ren YD, Yu XF, Liu XB, Zhang RM, Fang K, Pan JS.

Sci Rep. 2017 Mar 10;7:43752. doi: 10.1038/srep43752.

19.

The Relationship between the Growth Hormone/Insulin-like Growth Factor System and the Histological Features of Nonalcoholic Fatty Liver Disease.

Chishima S, Kogiso T, Matsushita N, Hashimoto E, Tokushige K.

Intern Med. 2017;56(5):473-480. doi: 10.2169/internalmedicine.56.7626. Epub 2017 Mar 1.

20.

Widespread GLI expression but limited canonical hedgehog signaling restricted to the ductular reaction in human chronic liver disease.

Grzelak CA, Sigglekow ND, Tirnitz-Parker JE, Hamson EJ, Warren A, Maneck B, Chen J, Patkunanathan B, Boland J, Cheng R, Shackel NA, Seth D, Bowen DG, Martelotto LG, Watkins DN, McCaughan GW.

PLoS One. 2017 Feb 10;12(2):e0171480. doi: 10.1371/journal.pone.0171480. eCollection 2017.

Supplemental Content

Support Center